Cargando…

Molecular Basis for the Neutralization of Tumor Necrosis Factor α by Certolizumab Pegol in the Treatment of Inflammatory Autoimmune Diseases

Monoclonal antibodies against TNFα, including infliximab, adalimumab, golimumab, and certolizumab pegol, are widely used for the treatment of the inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. Recently, the crystal structures of TNFα, in complex with the Fab fragm...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jee Un, Shin, Woori, Son, Ji Young, Yoo, Ki-Young, Heo, Yong-Seok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5297857/
https://www.ncbi.nlm.nih.gov/pubmed/28124979
http://dx.doi.org/10.3390/ijms18010228
_version_ 1782505798559072256
author Lee, Jee Un
Shin, Woori
Son, Ji Young
Yoo, Ki-Young
Heo, Yong-Seok
author_facet Lee, Jee Un
Shin, Woori
Son, Ji Young
Yoo, Ki-Young
Heo, Yong-Seok
author_sort Lee, Jee Un
collection PubMed
description Monoclonal antibodies against TNFα, including infliximab, adalimumab, golimumab, and certolizumab pegol, are widely used for the treatment of the inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. Recently, the crystal structures of TNFα, in complex with the Fab fragments of infliximab and adalimumab, have revealed the molecular mechanisms of these antibody drugs. Here, we report the crystal structure of TNFα in complex with the Fab fragment of certolizumab pegol to clarify the precise antigen-antibody interactions and the structural basis for the neutralization of TNFα by this therapeutic antibody. The structural analysis and the mutagenesis study revealed that the epitope is limited to a single protomer of the TNFα trimer. Additionally, the DE loop and the GH loop of TNFα play critical roles in the interaction with certolizumab, suggesting that this drug exerts its effects by partially occupying the receptor binding site of TNFα. In addition, a conformational change of the DE loop was induced by certolizumab binding, thereby interrupting the TNFα-receptor interaction. A comprehensive comparison of the interactions of TNFα blockers with TNFα revealed the epitope diversity on the surface of TNFα, providing a better understanding of the molecular mechanism of TNFα blockers. The accumulation of these structural studies can provide a basis for the improvement of therapeutic antibodies against TNFα.
format Online
Article
Text
id pubmed-5297857
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-52978572017-02-10 Molecular Basis for the Neutralization of Tumor Necrosis Factor α by Certolizumab Pegol in the Treatment of Inflammatory Autoimmune Diseases Lee, Jee Un Shin, Woori Son, Ji Young Yoo, Ki-Young Heo, Yong-Seok Int J Mol Sci Article Monoclonal antibodies against TNFα, including infliximab, adalimumab, golimumab, and certolizumab pegol, are widely used for the treatment of the inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. Recently, the crystal structures of TNFα, in complex with the Fab fragments of infliximab and adalimumab, have revealed the molecular mechanisms of these antibody drugs. Here, we report the crystal structure of TNFα in complex with the Fab fragment of certolizumab pegol to clarify the precise antigen-antibody interactions and the structural basis for the neutralization of TNFα by this therapeutic antibody. The structural analysis and the mutagenesis study revealed that the epitope is limited to a single protomer of the TNFα trimer. Additionally, the DE loop and the GH loop of TNFα play critical roles in the interaction with certolizumab, suggesting that this drug exerts its effects by partially occupying the receptor binding site of TNFα. In addition, a conformational change of the DE loop was induced by certolizumab binding, thereby interrupting the TNFα-receptor interaction. A comprehensive comparison of the interactions of TNFα blockers with TNFα revealed the epitope diversity on the surface of TNFα, providing a better understanding of the molecular mechanism of TNFα blockers. The accumulation of these structural studies can provide a basis for the improvement of therapeutic antibodies against TNFα. MDPI 2017-01-23 /pmc/articles/PMC5297857/ /pubmed/28124979 http://dx.doi.org/10.3390/ijms18010228 Text en © 2017 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lee, Jee Un
Shin, Woori
Son, Ji Young
Yoo, Ki-Young
Heo, Yong-Seok
Molecular Basis for the Neutralization of Tumor Necrosis Factor α by Certolizumab Pegol in the Treatment of Inflammatory Autoimmune Diseases
title Molecular Basis for the Neutralization of Tumor Necrosis Factor α by Certolizumab Pegol in the Treatment of Inflammatory Autoimmune Diseases
title_full Molecular Basis for the Neutralization of Tumor Necrosis Factor α by Certolizumab Pegol in the Treatment of Inflammatory Autoimmune Diseases
title_fullStr Molecular Basis for the Neutralization of Tumor Necrosis Factor α by Certolizumab Pegol in the Treatment of Inflammatory Autoimmune Diseases
title_full_unstemmed Molecular Basis for the Neutralization of Tumor Necrosis Factor α by Certolizumab Pegol in the Treatment of Inflammatory Autoimmune Diseases
title_short Molecular Basis for the Neutralization of Tumor Necrosis Factor α by Certolizumab Pegol in the Treatment of Inflammatory Autoimmune Diseases
title_sort molecular basis for the neutralization of tumor necrosis factor α by certolizumab pegol in the treatment of inflammatory autoimmune diseases
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5297857/
https://www.ncbi.nlm.nih.gov/pubmed/28124979
http://dx.doi.org/10.3390/ijms18010228
work_keys_str_mv AT leejeeun molecularbasisfortheneutralizationoftumornecrosisfactorabycertolizumabpegolinthetreatmentofinflammatoryautoimmunediseases
AT shinwoori molecularbasisfortheneutralizationoftumornecrosisfactorabycertolizumabpegolinthetreatmentofinflammatoryautoimmunediseases
AT sonjiyoung molecularbasisfortheneutralizationoftumornecrosisfactorabycertolizumabpegolinthetreatmentofinflammatoryautoimmunediseases
AT yookiyoung molecularbasisfortheneutralizationoftumornecrosisfactorabycertolizumabpegolinthetreatmentofinflammatoryautoimmunediseases
AT heoyongseok molecularbasisfortheneutralizationoftumornecrosisfactorabycertolizumabpegolinthetreatmentofinflammatoryautoimmunediseases